http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019511903-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7155 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6878 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5044 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2019511903-A |
| titleOfInvention | Methods of immunogenicity regulation |
| abstract | Ex vivo determination of increased tumor immunogenicity of tumor biopsies is used as a guide to identify tumor immunotherapy in patients. Most preferably, the ex vivo test will then include exposure of the biopsy sample to a stressed condition producing pre-treated tumor cells which will then be assayed using immunocompetent cells for increased activation or activity. I will. Test conditions include exposure of the biopsy sample to an immunostimulatory composition, antibodies to neoepitopes, and / or altered cells, and the increase in immunogenicity is preferably by exposure to T cells and / or NK cells. It is determined. [Selected figure] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11585805-B2 |
| priorityDate | 2016-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 453.